Having trouble accessing articles? Reset your cache.

Celgene, Cyclacel cancer news

Cyclacel will sell Celgene patents covering the use of romidepsin injection in T cell lymphomas for $5.5 million. In

Read the full 198 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE